Astex Pharmaceuticals to Present a Novel Targeted Approach to the Treatment of HCV at the AASLD Meeting
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery, development and commercialization of novel
therapeutics, announced that it will present data on its novel,
first-in-class direct acting antiviral agents (DAA) against Hepatitis C
Virus (HCV) at the 62nd Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) in San Francisco,
November 4-8, 2011.
The following presentations are scheduled for Saturday, November 5, 2011
at 2:00 pm PT during poster session R06: HCV Therapy: Preclinical and
Early Clinical Development.
-
Abstract #371: Cell based replicon validation of novel HCV NS3
allosteric inhibitors result in a new therapeutic approach
-
Abstract #352: Discovery of a novel allosteric binding site on the
full length HCV NS3/4a enzyme by fragment-based X-ray screening
Astex Pharmaceuticals has used its proprietary fragment-based drug
discovery approach, Pyramid™, to target a previously unknown allosteric
binding site on the full length HCV NS3 protease - helicase complex.
Agents acting at this site have a novel mode of action and a different
resistance profile compared to NS3 protease inhibitors. The NS3 protein
is essential for viral replication and represents a validated HCV
therapeutic target. These data represent a new approach to development
of targeted agents to treat HCV infection. As part of its presentations,
Astex Pharmaceuticals scientists will present on the discovery of the
allosteric site using their Pyramid approach and on initial work aimed
at validating the anti-viral activity of these first-in-class
fragment-derived allosteric inhibitors.
Astex Pharmaceuticals is currently selecting a clinical candidate with a
view to filing an IND in 2012. This research program, which has been
supported with £2 million of funding from the Wellcome Trust Seeding
Drug Discovery initiative, is wholly owned by Astex Pharmaceuticals.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery, development, and
commercialization of novel therapeutics with a focus on cancer. The
Company is developing a proprietary pipeline of novel cancer therapies,
will selectively in-license assets possessing a strategic fit with an
attractive cost — value ratio, and is creating de-risked products for
partnership with leading pharmaceutical companies. Astex
Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for
Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
Astex Pharmaceuticals, Inc.
Corporate Communications & Marketing
Timothy
L. Enns, 925-560-2810
Senior Vice President
tim.enns@astx.com
or
The
Trout Group
Alan Roemer, 646-378-2945
Managing Director
aroemer@troutgroup.com
or
Astex
Pharmaceuticals, Inc.
Investor Relations
Susanna Chau,
925-560-2845
Manager
susanna.chau@astx.com
or
College
Hill
Melanie Toyne-Sewell (Europe), +44 20 7866 7866
Rebecca
Skye Dietrich (US), 857-241-0795
astex@collegehill.com
Source: Astex Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top
Delicious
Digg
Facebook
LinkedIn
Twitter
Mixx
Yahoo! Buzz